Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ARCT 
Arcturus Therapeutics Holdings Inc (ARCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: ARCT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $35.5
1 Year Target Price $35.5
| 8 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -57% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 192.92M USD | Price to earnings Ratio - | 1Y Target Price 35.5 |
Price to earnings Ratio - | 1Y Target Price 35.5 | ||
Volume (30-day avg) 11 | Beta 2.07 | 52 Weeks Range 5.85 - 24.17 | Updated Date 11/30/2025 |
52 Weeks Range 5.85 - 24.17 | Updated Date 11/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.46 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-10 | When - | Estimate 5.53 | Actual -0.49 |
Profitability
Profit Margin -68.35% | Operating Margin (TTM) -96.27% |
Management Effectiveness
Return on Assets (TTM) -15% | Return on Equity (TTM) -27.43% |
Valuation
Trailing PE - | Forward PE 2.48 | Enterprise Value 38548126 | Price to Sales(TTM) 1.98 |
Enterprise Value 38548126 | Price to Sales(TTM) 1.98 | ||
Enterprise Value to Revenue 0.45 | Enterprise Value to EBITDA -25.67 | Shares Outstanding 28412537 | Shares Floating 26275346 |
Shares Outstanding 28412537 | Shares Floating 26275346 | ||
Percent Insiders 7.53 | Percent Institutions 85.6 |
Upturn AI SWOT
Arcturus Therapeutics Holdings Inc
Company Overview
History and Background
Arcturus Therapeutics Holdings Inc. was founded in 2013. It's a global late-stage clinical messenger RNA medicines and vaccines company pursuing medicines for respiratory, liver, and other diseases.
Core Business Areas
- mRNA Medicines: Development of mRNA-based therapeutics and vaccines.
- Nucleic Acid Medicines: Focus on RNA medicines for various therapeutic areas.
Leadership and Structure
Joseph Payne (President & CEO). The company has a board of directors and a management team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- ARCT-154 (COVID-19 vaccine): mRNA COVID-19 vaccine candidate. Competitors include Pfizer (PFE), Moderna (MRNA), and Novavax (NVAX). Market share and revenue data for ARCT-154 are not publicly available in a disaggregated manner.
- ARCALIS (LUNAR-OTC): mRNA therapeutic for Ornithine Transcarbamylase (OTC) deficiency. Competitors are limited, as it addresses a rare disease. Market share and revenue data for ARCALIS are not yet available. Potential competitive therapies would be gene therapies in development from other companies.
Market Dynamics
Industry Overview
The mRNA therapeutics and vaccines market is rapidly growing, driven by the success of mRNA COVID-19 vaccines and increasing investment in mRNA technology.
Positioning
Arcturus is a late-stage clinical company focusing on mRNA medicines and vaccines. Competitive advantages include proprietary delivery technologies like LUNAR.
Total Addressable Market (TAM)
The TAM for mRNA therapeutics is estimated to be billions of dollars and growing. Arcturus is positioned to capture a share of this market with its pipeline and delivery technologies.
Upturn SWOT Analysis
Strengths
- Proprietary mRNA delivery technology (LUNAR)
- Strong intellectual property portfolio
- Late-stage clinical pipeline
- Experienced management team
Weaknesses
- Reliance on mRNA technology, which is still relatively new
- Limited product revenue compared to larger competitors
- Potential regulatory hurdles
- Need for further capital raising
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of mRNA technology to new therapeutic areas
- Successful commercialization of pipeline products
- Increased government funding for mRNA research
Threats
- Competition from larger pharmaceutical companies
- Patent challenges
- Clinical trial failures
- Changes in regulatory landscape
Competitors and Market Share
Key Competitors
- MRNA
- BNTX
- LLY
Competitive Landscape
Arcturus faces intense competition from established pharmaceutical companies and other mRNA technology companies. Arcturus has a differentiated mRNA technology and focuses on niche areas such as rare disease which could give it an edge.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by clinical trial progress and partnerships.
Future Projections: Future growth depends on successful clinical trial outcomes and commercialization.
Recent Initiatives: Focus on advancing clinical trials for ARCT-154 and ARCALIS, expanding partnerships, and developing new mRNA technologies.
Summary
Arcturus Therapeutics is a growing mRNA-focused company with promising clinical assets. Success hinges on positive clinical trial results and effective commercialization. Competition and financial constraints pose significant challenges, but proprietary technology and strategic partnerships offer potential for growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Arcturus Therapeutics Holdings Inc. Investor Relations
- SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data are estimates and may not be precise. Financial data should be verified with official sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arcturus Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-04-16 | Founder, President, CEO & Director Mr. Joseph E. Payne M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 174 | Website https://arcturusrx.com |
Full time employees 174 | Website https://arcturusrx.com | ||
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.